StockData
Anbio Biotechnology logo

Anbio Biotechnology (NNNN) stock

NNNNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 7, 2026Score 11/30
$3.65−0.23 (-5.93%)

Close on Nov 17, 2026Market cap $525.20MP/E 24.8Yield –

Anbio Biotechnology cash

Cash and short-term investments held at the end of each period.

Anbio Biotechnology's cash was $11.90M at Dec 31, 2025. For fiscal 2025 it was $11.90M, up 1.2% from the year before. The highest annual figure on record is $11.90M in fiscal 2025.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$11.90M+1.2%
FY2024Dec 31, 2024$11.76M+21.4%
FY2023Dec 31, 2023$9.69M+36.4%
FY2022Dec 31, 2022$7.10M+69.9%
FY2021Dec 31, 2021$4.18M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025$11.90M+184.6%
Q4 FY2024Dec 31, 2024$11.76M–
Q4 FY2023Dec 31, 2023$9.69M–
Q4 FY2022Dec 31, 2022$7.10M–
Q4 FY2021Dec 31, 2021$4.18M–

More Anbio Biotechnology figures

See a number that looks wrong?